April 4, 2024Diabetes TherapyOpen Access

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial evaluates luseogliflozin impact on myocardial flow reserve in type 2 diabetes, highlighting mechanisms of cardioprotection.

Trial protocol investigates whether luseogliflozin improves myocardial flow reserve in patients diagnosed with type 2 diabetes mellitus.
Primary outcome assesses change in myocardial flow reserve using 13N-ammonia positron emission tomography across 40 patients at 24 weeks.
Prospective randomized trial compares the SGLT2 inhibitor against active control in stable coronary disease, with final results pending.

Tamanaha et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates luseogliflozin impact on myocardial flow reserve in type 2 diabetes, highlighting mechanisms of cardioprotection.